Akari Therapeutics

- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.akaritx.com
Akari Therapeutics Secures India Patent for Novel Spliceosome-Inhibiting ADC Payload Technology
Akari Therapeutics received Patent No. 562,919 from India's Intellectual Property Office for its novel PH1 payload, a spliceosome inhibitor that disrupts RNA splicing to kill cancer cells and activate immune responses.
Akari Therapeutics Appoints Mark F. Kubik to Lead Oncology Business Development for Novel ADC Platform
Akari Therapeutics has appointed Mark F. Kubik as Head of Business Development - Oncology, bringing over 25 years of experience in transformative deal creation across oncology therapeutics.
Akari Therapeutics Secures $7.6 Million Private Placement to Advance Novel ADC Platform
Akari Therapeutics (NASDAQ: AKTX) has successfully priced a $7.6 million private placement financing round, with funds directed toward its spliceosome inhibitor payload ADC technology platform.
NorthSea Therapeutics Strengthens Executive Team with Strategic CFO and CMO Appointments
NorthSea Therapeutics appoints Melissa Bradford-Klug as CFO/CBO, bringing over 20 years of experience and $6 billion in financing track record to advance metabolic disease therapies.
Bullous Pemphigoid Pipeline Heats Up as Multiple Therapies Advance in Clinical Trials
Bullous pemphigoid (BP), a subepidermal autoimmune blistering disease primarily affecting the elderly, currently lacks approved therapies in the United States, creating a significant unmet need.